ArticleMolecular cancer2024

A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation.

Xin Peng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.